Skip to content
Screener

Exelixis EXEL Collaboration services revenues — Total revenues

Other product segments

Gross product revenues
$812.78M+9.1%
Discounts and allowances
-$239.76M-6.4%
License revenues
$59.81M+21.3%
Collaboration
$55.67M+15.4%

Similar metrics at other companies

Supernus Pharmaceuticals logo
SUPNCollaboration revenue (ZURZUVAE) — Total revenues
$27.64M
Quanterix Corporation logo
QTRXCollaboration and license revenue — Total revenues
$560K-27.4%
Neurocrine Biosciences logo
NBIXCollaboration revenues — Total revenues
$3.5M-60.7%
Kinetik Holdings logo
KNTKService revenue — Total revenues
$93.77M-26.7%
Agilon Health logo
AGLMedical services revenue — Total revenues
$1.49B+7.2%
Arcus Biosciences logo
RCUSOther collaboration — Total revenues
$25M+213%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
License revenues$50,539$39,540$94,071$73,519
Collaboration services revenues(4,532)(2,507)(8,496)(3,780)
Total collaboration revenues$46,007$37,033$85,575$69,739

Item 1. Financial Statements.

FAQ

What is Exelixis's collaboration services revenues — total revenues?
Exelixis (EXEL) reported collaboration services revenues — total revenues of -$4.53M in Q2 2026.
How has Exelixis's collaboration services revenues — total revenues changed year-over-year?
Exelixis's collaboration services revenues — total revenues decreased by 80.8% year-over-year, from -$2.51M to -$4.53M.
What is the long-term trend for Exelixis's collaboration services revenues — total revenues?
Over 4 years (2021 to 2025), Exelixis's collaboration services revenues — total revenues has grown at a -36.9% compound annual growth rate (CAGR), from $107.76M to -$17.05M.
What does collaboration services revenues — total revenues mean?
This metric represents the aggregate revenue generated from collaboration and partnership agreements within a specific business segment. It encompasses all recognized income streams derived from joint development, licensing, or commercialization arrangements with third-party pharmaceutical partners. This figure reflects the overall financial performance and monetization success of the company's collaborative business model.

Ask your AI about Exelixis's collaboration services revenues — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude